<DOC>
	<DOCNO>NCT00316758</DOCNO>
	<brief_summary>This study evaluate long-term safety tolerability GK Activator ( 2 ) dose range 25mg - 100mg po bid , administer alone combination metformin , patient type 2 diabetes . Eligible patient complete study BM18248 ( GK Activator ( 2 ) monotherapy ) BM18249 ( GK Activator ( 2 ) metformin ) ; continue treatment regimen ( mono combination therapy ) receive initial study . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Evaluate Long-Term Safety Tolerability GK Activator ( 2 ) Patients With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>type 2 diabetic patient complete study BM18248 BM18249 ; patient consider investigator suitable long term treatment GK Activator ( 2 ) . type 1 diabetes mellitus ; woman pregnant , breastfeed use adequate contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>